Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect
- 11 March 2010
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 38 (6), 894-897
- https://doi.org/10.1124/dmd.109.030601
Abstract
The impact of the CYP2C19*17 allele on the pharmacokinetics of pantoprazole and omeprazole in previously studied children (n = 40) was explored. When pantoprazole area under the plasma concentration versus time curve (AUC) was examined as a function of CYP2C19 genotype, a significantly lower AUC was observed for subjects identified as CYP2C19*1/*1 and *1/*17. For pantoprazole, a statistically significant relationship was observed between CYP2C19 genotype and both dose-corrected AUC (p < 0.0001) and the apparent elimination rate constant (Kel; p = 0.0012); no significant genotype-phenotype relationships were observed for omeprazole.Keywords
This publication has 21 references indexed in Scilit:
- Impact of IntestinalCYP2C19Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant PatientsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2009
- Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of GreecePharmacogenomics, 2009
- Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safetyPharmacological Research, 2008
- Off-label use of medicines in children: can available evidence avoid useless paediatric trials?European Journal of Clinical Pharmacology, 2008
- The ontogeny of drug metabolism enzymes and implications for adverse drug eventsPharmacology & Therapeutics, 2008
- Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in CaucasiansBritish Journal of Clinical Pharmacology, 2008
- Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese populationBritish Journal of Clinical Pharmacology, 2008
- Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemInternational journal of clinical pharmacology and therapeutics, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsCancer Cell, 2006